Document is current
Any future updates will be listed below
-
Authors
Aguilar, Gerardo
Ruiz-Garbajosa, Patricia
Periañez Parraga, Leonor
Maroto-Díaz, Marta
de Ceano-Vivas, María del Carmen
Villacampa Lordan, Alba https://orcid.org/0009-0009-0152-6294
Arranz Gonzalo, Sara
de Lossada Juste, Alfonso
Moya-Alarcón, Carlota https://orcid.org/0000-0003-4873-7362
Gheorghe, Maria
Torre-Cisneros, Julián https://orcid.org/0000-0003-1529-6302
-
Funding
Funding for this research was provided by:
Pfizer Spain
- License Information
-
More Information
Article History
Received: 29 August 2025
Accepted: 20 October 2025
First Online: 26 November 2025
Declarations
:
: Gerardo Aguilar received financial support for speaking at meetings organized on behalf of Shionogi, Gilead, Merck Sharp and Dohme (MSD), Mundipharma, Pfizer, as well as unrestricted research grants from Shionogi, MSD and Pfizer. Patricia Ruiz-Garbajosa has received honoraria from Advanz and Viatris Pharmaceuticals for consulting and from Pfizer, Shionogy, MSD and Menarini for training activities. Leonor Periañez Parraga has received consulting honoraria from Advanz and MSD. Training activities have been funded by Pfizer, Shionogy, MSD, Menarini, and Advanz. María Maroto-Díaz, María del Carmen de Ceano-Vivas, Alfonso De Lossada Juste, Carlota Moya-Alarcón and Maria Gheorghe are employees of Pfizer and may hold Pfizer stock. Alba Villacampa Lordan and Sara Arranz Gonzalo are employees of Hygeia Consulting. Julián Torre-Cisneros has received consulting honoraria from Shionogy, Advanz and MSD. Training activities have been funded by Pfizer, Shionogy, MSD, Menarini, and Advanz.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
